A recent study has reported that an intermediate-risk HB subtype, named C2B, has higher expression of the mesenchymal marker vimentin than the good-prognosis HB subtype C1 and the proliferative high-risk C2A tumors [9]. The gene discussed is VIM; the disease is hemoglobin measurement.